Suppr超能文献

新型WallFlex肠道支架在恶性胃出口梗阻姑息治疗中的疗效与安全性(DUOFLEX研究):一项前瞻性多中心研究

Efficacy and safety of the new WallFlex enteral stent in palliative treatment of malignant gastric outlet obstruction (DUOFLEX study): a prospective multicenter study.

作者信息

van Hooft Jeanin E, Uitdehaag Madeleen J, Bruno Marco J, Timmer Robin, Siersema Peter D, Dijkgraaf Marcel G W, Fockens Paul

机构信息

Academic Medical Center, Amsterdam, Netherlands.

出版信息

Gastrointest Endosc. 2009 May;69(6):1059-66. doi: 10.1016/j.gie.2008.07.026. Epub 2009 Jan 18.

Abstract

BACKGROUND

Gastric outlet obstruction (GOO) is most commonly a complication of advanced distal gastric, periampullary, or duodenal malignancy. Palliation of obstruction is the primary aim of treatment in most of these patients. Self-expandable metal stents have emerged as an effective treatment option.

OBJECTIVE

Our purpose was to investigate the efficacy and safety of a newly developed enteral metal stent (WallFlex).

DESIGN

Prospective multicenter cohort study.

SETTING

Three tertiary referral centers (2 academic).

PATIENTS

Fifty-one consecutive patients with symptomatic malignant GOO from January 2005 to February 2006.

INTERVENTION

Placement of a self-expandable metallic stent (WallFlex).

MAIN OUTCOME MEASUREMENTS

The primary end point was defined as improvement of the GOO scoring system for the remainder of the patients' lives. Secondary end points focused on efficacy and safety and global quality of life.

RESULTS

The Gastric Outlet Obstruction Scoring System score improved (P < .001), the body mass index decreased (P < .001), and the World Health Organization performance score improved (P = .002) when the score before stenting was compared with the mean score until death. Global quality of life did not improve. Technical and clinical success was achieved in 98% and 84% of the patients. Median survival was 62 days (75% alive at 35 days, 25% alive at 156 days). Median stent patency was 307 days (75% functional at 135 days, 25% functional at 470 days). Stent dysfunction was proved in 7 patients (14%), migration in 1 (2%), and tumor overgrowth or ingrowth in 6 (12%).

LIMITATIONS

Lack of a control group.

CONCLUSION

Placement of a WallFlex enteral stent in patients with nonresectable malignant GOO is safe and provides a statistically significant and clinically relevant relief of obstructive symptoms with a low need for reintervention.

摘要

背景

胃出口梗阻(GOO)最常见于晚期远端胃癌、壶腹周围癌或十二指肠恶性肿瘤。缓解梗阻是大多数此类患者治疗的主要目标。自膨式金属支架已成为一种有效的治疗选择。

目的

我们的目的是研究一种新开发的肠道金属支架(WallFlex)的疗效和安全性。

设计

前瞻性多中心队列研究。

地点

三个三级转诊中心(2个学术中心)。

患者

2005年1月至2006年2月连续纳入的51例有症状的恶性胃出口梗阻患者。

干预

置入自膨式金属支架(WallFlex)。

主要观察指标

主要终点定义为患者余生胃出口梗阻评分系统的改善。次要终点集中在疗效、安全性和总体生活质量。

结果

将置入支架前的评分与直至死亡的平均评分相比,胃出口梗阻评分系统评分改善(P <.001),体重指数下降(P <.001),世界卫生组织体能状态评分改善(P =.002)。总体生活质量未改善。98%的患者获得技术成功,84%的患者获得临床成功。中位生存期为62天(35天时75%存活,156天时25%存活)。中位支架通畅时间为307天(1个35天时75%功能正常,470天时25%功能正常)。7例患者(14%)证实支架功能障碍,1例(2%)支架移位,6例(12%)肿瘤过度生长或长入。

局限性

缺乏对照组。

结论

对于不可切除的恶性胃出口梗阻患者,置入WallFlex肠道支架是安全的,能在统计学上显著且临床上切实缓解梗阻症状,再次干预需求低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验